0000000000669861

AUTHOR

Irene Berto

showing 2 related works from this author

Reduced Admissions for Cerebrovascular Events during COVID-19 Outbreak in Italy

2020

Supplemental Digital Content is available in the text.

disease outbreakMalemedicine.medical_treatment030204 cardiovascular system & hematologyItaly; cerebral hemorrhage; disease outbreaks; incidence; ischemic attack transient0302 clinical medicineEpidemiology80 and overMedicineischemic attack transientThrombolytic Therapy10178Acute ischemic stroke10177ThrombectomyAged 80 and overIschemic AttackTransientIncidence (epidemiology)Endovascular ProceduresMiddle AgedHospitalization1006210183ItalyComputingMethodologies_DOCUMENTANDTEXTPROCESSINGSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinecerebral hemorrhage; disease outbreaks; incidence; ischemic attack transient; Italy; Aged; Aged 80 and over; COVID-19; Cerebral Hemorrhage; Endovascular Procedures; Female; Hospitalization; Humans; Ischemic Attack Transient; Ischemic Stroke; Italy; Male; Middle Aged; Thrombectomy; Thrombolytic Therapymedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RevascularizationSettore MED/261015203 medical and health sciencesHumansAgedIschemic StrokeAdvanced and Specialized Nursingcerebral hemorrhagebusiness.industryOutbreakCOVID-19Emergency medicinedisease outbreaksincidenceBrief ReportsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRI…

2022

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A. The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive BRV in patients with PSE treated in a real-world setting. Methods: This was a subgroup analysis of patients with PSE included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). The BRIVAFI…

AdultAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; StrokeCerebrovascular diseasesSettore MED/26Antiseizure medication Brivaracetam Focal seizures Stroke Cerebrovascular diseasesFocal seizuresDouble-Blind MethodDrug TherapySeizuresHumansAgedRetrospective StudiesAntiseizure medicationEpilepsyGeneral MedicineMiddle AgedPyrrolidinonesStrokeTreatment OutcomeNeurologyItalyCombinationBrivaracetamAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; Stroke; Adult; Aged; Anticonvulsants; Double-Blind Method; Drug Therapy Combination; Humans; Italy; Middle Aged; Pyrrolidinones; Retrospective Studies; Seizures; Treatment Outcome; Epilepsy; StrokeDrug Therapy CombinationAnticonvulsantsNeurology (clinical)
researchProduct